Building on their previous observation of intrinsic resistance of BRAF mutant colorectal cancers to epidermal growth factor receptor (EGFR) activation [11], these investigators [9] explored a potential role for EGFR in acquired resistance to BRAF inhibition in BRAF mutant melanoma. This evidence concerns the gene BRAF and colorectal cancer.